Although prior structural analyses identified the ACE2 inhibitor N-(2-Aminoethyl)-1-aziridineethanamine (NAAE), which inhibits SARS cell fusion in vitro, as a potential therapy for SARS [40], this compound has not been developed further. Here, ACE2 is linked to severe acute respiratory syndrome.